FRIENDS OF CYMRU SICKLE CELL AND THALASSAEMIA C.I.C.

Company limited by guarantee

Company Registration Number:
13142747 (England and Wales)

Unaudited statutory accounts for the year ended 31 January 2025

Period of accounts

Start date: 1 February 2024

End date: 31 January 2025

FRIENDS OF CYMRU SICKLE CELL AND THALASSAEMIA C.I.C.

Contents of the Financial Statements

for the Period Ended 31 January 2025

Directors report
Profit and loss
Balance sheet
Additional notes
Balance sheet notes
Community Interest Report

FRIENDS OF CYMRU SICKLE CELL AND THALASSAEMIA C.I.C.

Directors' report period ended 31 January 2025

The directors present their report with the financial statements of the company for the period ended 31 January 2025

Directors

The directors shown below have held office during the whole of the period from
1 February 2024 to 31 January 2025

FAITH WALKER
P D PALMER
J A E HARRY
M L FRECKLETON


The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006

This report was approved by the board of directors on
18 September 2025

And signed on behalf of the board by:
Name: FAITH WALKER
Status: Director

FRIENDS OF CYMRU SICKLE CELL AND THALASSAEMIA C.I.C.

Profit And Loss Account

for the Period Ended 31 January 2025

2025 2024


£

£
Turnover: 0 0
Cost of sales: 0 0
Gross profit(or loss): 0 0
Distribution costs: 0 0
Administrative expenses: ( 42,728 ) ( 56,910 )
Other operating income: 47,577 90,493
Operating profit(or loss): 4,849 33,583
Interest receivable and similar income: 0 0
Interest payable and similar charges: 0 0
Profit(or loss) before tax: 4,849 33,583
Tax: 0 0
Profit(or loss) for the financial year: 4,849 33,583

FRIENDS OF CYMRU SICKLE CELL AND THALASSAEMIA C.I.C.

Balance sheet

As at 31 January 2025

Notes 2025 2024


£

£
Fixed assets
Intangible assets:   0 0
Tangible assets: 3 3,076 3,569
Investments:   0 0
Total fixed assets: 3,076 3,569
Current assets
Stocks:   0 0
Debtors: 4 303 0
Cash at bank and in hand: 35,989 31,546
Investments:   0 0
Total current assets: 36,292 31,546
Prepayments and accrued income: 0 0
Creditors: amounts falling due within one year: 5 ( 936 ) ( 1,532 )
Net current assets (liabilities): 35,356 30,014
Total assets less current liabilities: 38,432 33,583
Creditors: amounts falling due after more than one year:   0 0
Provision for liabilities: 0 0
Accruals and deferred income: 0 0
Total net assets (liabilities): 38,432 33,583
Members' funds
Profit and loss account: 38,432 33,583
Total members' funds: 38,432 33,583

The notes form part of these financial statements

FRIENDS OF CYMRU SICKLE CELL AND THALASSAEMIA C.I.C.

Balance sheet statements

For the year ending 31 January 2025 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 18 September 2025
and signed on behalf of the board by:

Name: FAITH WALKER
Status: Director

The notes form part of these financial statements

FRIENDS OF CYMRU SICKLE CELL AND THALASSAEMIA C.I.C.

Notes to the Financial Statements

for the Period Ended 31 January 2025

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

    Tangible fixed assets depreciation policy

    Tangible assets are initially recorded at cost, and subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses. An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in equity, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation, is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in equity in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in equity in respect of that asset, the excess shall be recognised in profit or loss.

FRIENDS OF CYMRU SICKLE CELL AND THALASSAEMIA C.I.C.

Notes to the Financial Statements

for the Period Ended 31 January 2025

  • 2. Employees

    2025 2024
    Average number of employees during the period 2 2

FRIENDS OF CYMRU SICKLE CELL AND THALASSAEMIA C.I.C.

Notes to the Financial Statements

for the Period Ended 31 January 2025

3. Tangible assets

Land & buildings Plant & machinery Fixtures & fittings Office equipment Motor vehicles Total
Cost £ £ £ £ £ £
At 1 February 2024 7,737 7,737
Additions 533 533
Disposals
Revaluations
Transfers
At 31 January 2025 8,270 8,270
Depreciation
At 1 February 2024 4,168 4,168
Charge for year 1,026 1,026
On disposals
Other adjustments
At 31 January 2025 5,194 5,194
Net book value
At 31 January 2025 3,076 3,076
At 31 January 2024 3,569 3,569

FRIENDS OF CYMRU SICKLE CELL AND THALASSAEMIA C.I.C.

Notes to the Financial Statements

for the Period Ended 31 January 2025

4. Debtors

2025 2024
£ £
Other debtors 303 0
Total 303 0

FRIENDS OF CYMRU SICKLE CELL AND THALASSAEMIA C.I.C.

Notes to the Financial Statements

for the Period Ended 31 January 2025

5. Creditors: amounts falling due within one year note

2025 2024
£ £
Taxation and social security 0 632
Other creditors 936 900
Total 936 1,532

COMMUNITY INTEREST ANNUAL REPORT

FRIENDS OF CYMRU SICKLE CELL AND THALASSAEMIA C.I.C.

Company Number: 13142747 (England and Wales)

Year Ending: 31 January 2025

Company activities and impact

During the financial year ending January 31, 2025, Friends of Cymru Sickle Cell and Thalas-saemia CIC (FOCSCT) continuously consulted with our members and stakeholders to ensure that we delivered activities and tailored individual support that benefited individuals and fami-lies, as well as positively impacted the community we serve. As a result, we: 1. Improved Financial Support for Families: By assisting families with their Disability Living Allowance (DLA) applications and accompanying them through the appeal process, FOCSCT helped secure financial aid for families. This support has been crucial in covering the extra costs associated with raising a disabled child, thereby relieving some of the financial burden on these families. 2. Stable Housing Solutions: FOCSCT played a pivotal role in helping families transition from temporary to permanent accommodation that meets their specific disability needs. By covering decorating costs and coordinating with occupational health services, families are now in safer, more suitable living conditions, which positively affects their overall well-being. 3. Access to Recreational and Supportive Activities: The Second Saturday Club (2SC) has created a safe and enjoyable environment for children and young people affected by SCD and TD to connect with peers, engage in activities, and share their experiences. This fosters a sense of community, belonging, and emotional support among the participants. 4. Enhanced Knowledge and Confidence: The community education event on gene therapy and editing provided families with valuable information and answered critical questions, lead-ing to a greater understanding of their conditions. Increased knowledge enables families to make informed decisions about their healthcare, thereby improving their confidence in advo-cating for their needs. 5. Empowerment of Young People: By establishing a youth committee and involving young people in the decision-making process, FOCSCT has empowered the next generation to voice their concerns and needs. This not only boosts their self-esteem but also engages them in civ-ic activities, enabling them to influence the direction of programmes that affect their lives. 6. Increased Participation in Health and Wellness Activities: Support for families to partici-pate in initiatives like Over The Wall Camp provides children and their siblings with unique experiences that promote confidence, friendship, and personal development. These activities help mitigate feelings of isolation and in still a sense of normalcy in their lives. 7. Building Connections with Health Professionals: The partnerships developed with health professionals and community leaders during events encourage ongoing dialogues be-tween families and health services. This can lead to better health outcomes and a more re-sponsive healthcare system for those affected by Sickle Cell Disorder (SCD) and Thalassae-mia Disorder (TD). 8. Advocating for equitable health outcomes: The impact of providing emergency supplies during hospital visits is significant. By supplying necessities, we help reduce the stress and anxiety families face during hospital admissions, preserving their dignity. Additionally, advocat-ing for equitable access to healthcare and necessary medications helps address systemic in-equalities, thereby improving overall patient outcomes. These efforts foster community support and compassion for vulnerable individuals in challenging situations. Overall, these impacts contribute to a stronger, more informed, and more resilient community, thereby improving the quality of life for families affected by SCD and TD.

Consultation with stakeholders

We are committed to empowering the residents of Wales who are affected by Sickle Cell Dis-order (SCD) and Thalassaemia Disorder (TD). As a beneficiary-led organisation, we play a pivotal role in providing critical resources and support to individuals and families in our com-munities. SCD and TD are severe, inherited blood conditions that create lifelong challenges with no universal cure. Individuals facing these conditions encounter significant hurdles in their daily lives, which impact employment, education, healthcare, housing, and access and enhance their quality of life. By uniting our efforts, we can foster a stronger, more inclusive community for everyone in Wales. Our commitment to listening and engaging is evident through continuous consultation via WhatsApp, personalised meetings with individuals and families, our "Let's Talk" sessions on Zoom, and the S2C initiative. These interactions enable us to gather valuable written and ver-bal feedback regularly. The insights from our stakeholders play a crucial role in shaping and guiding FOCSCT's activities, resulting in FOCSCT taking action. As a result, and thanks to di-rect input from those we serve, we successfully applied for and received funding from two key grants: 1. BBC Children in Need We Move Fund. 2. Lloyds Bank Foundation – Deaf and Disabled People's Organisation (DDPO) Fund. Actions Taken FOCSCT regularly holds meetings with families to conduct welfare checks. We have support-ed families with their Disability Living Allowance (DLA) applications by assisting them in filling out the forms and guiding them through the appeal process by connecting them with relevant agencies. Additionally, FOCSCT accompanied families to the tribunal, resulting in a family be-ing awarded DLA with their award backdated. This made a significant difference, as the award helped cover the extra costs of raising their disabled child. We also supported families transitioning from temporary accommodation to permanent hous-ing that meets their disability needs. FOCSCT covered the costs of decorating their new home and facilitated contact with occupational health services, which resulted in a stairlift being fitted for a child following a hip replacement operation. To ensure that children and young people could attend the Second Saturday Club (2SC), we covered transportation costs for families. This monthly youth club provides a safe, fun, and supportive environment for children and young people affected by sickle cell disorder (SCD) or thalassaemia (TD) to meet, receive support and advice, and engage in activities. Attendees share their feedback during each session, both verbally and in writing, which is crucial for the development of the 2SC. We organised and funded transportation for families, their advocates, additional carers, and supporters to attend a FOCSCT Community Education event titled "Thalassaemia and Sickle Cell Disorder in Wales – Is There a Better Future? Gene Therapy and Gene Editing for Tha-lassaemia and Sickle Cell Disorders." The discussion featured speakers who communicated directly and honestly with families about gene therapy and editing. Participants gained a deeper understanding, and families felt more confident asking questions. In Wales, where Sickle Cell and Thalassaemia are low-prevalence disorders, opportunities for informed dis-cussions are limited. In August 2024, the National Institute for Health and Care Excellence (NICE) approved managed access to gene editing for those with transfusion-dependent beta-thalassaemia through the NHS, and FOCSCT campaigned for similar access for people with SCD. We also assisted a family with transportation and provided them with appropriate clothing for their children to participate in Over The Wall Camp. This UK-based charity offers children and young people living with health challenges, along with their siblings and families, the chance to experience a world of mischief and magic. This participation helps families build friend-ships and confidence through meaningful and exciting activities in a safe environment. We successfully applied for grants from BBC Children in Need and the We Move Fund for a project called the Second Saturday Club (2SC). This youth club enables children and young people affected by SCD or TD to have fun while meeting others who share similar experienc-es. Additionally, the We Move Fund empowers young people by enabling them to deliver and organise spaces that amplify their voices. The young people established a youth committee and became involved in the organisation's decision-making process. The Youth Committee has met with the First Minister of Wales and senior leaders from Public Health Wales, as well as specialists from various health fields. Through these interactions, the youth gained confidence that enhanced their self-esteem in organising and planning interviews. This experience led to The S2C organising a film screen-ing and panel discussion at Chapter Art Centre in partnership with The New Black Film Col-lective. The panel included professionals such as the Clinical Psychologist from Clinical Neu-ropsychology and the Head of the Department of Child Health Psychology at Noah's Ark Chil-dren's Hospital for Wales. We provide emergency supplies for adults, children, and young people admitted to the hospi-tal. Due to the cost-of-living crisis, many families struggle to afford necessities when visiting healthcare facilities. This includes toiletries (such as shower gel, toothbrushes, and tooth-paste), pyjamas, sanitary products, and drinks to stay hydrated. Additionally, we advocate for equitable access to essential medications and pain relief, thereby addressing existing healthcare inequalities.

Directors' remuneration

The aggregate amount of emoluments paid to or receivable by directors in respect of qualifying services was £20,938. There were no other transactions or arrangements in connection with the remuneration of directors, or compensation for director’s loss of office, which require to be disclosed

Transfer of assets

No transfer of assets other than for full consideration

This report was approved by the board of directors on
29 September 2025

And signed on behalf of the board by:
Name: FAITH WALKER
Status: Director